Diabetologia

, Volume 30, Issue 7, pp 464–467 | Cite as

Peripheral nerve concentrations of glucose, fructose, sorbitol and myoinositol in diabetic and non-diabetic patients

  • P. J. Hale
  • M. Nattrass
  • S. H. Silverman
  • C. Sennit
  • C. M. Perkins
  • A. Uden
  • G. Sundkvist
Originals

Summary

Glucose, fructose, sorbitol and myoinositol concentrations were measured in biopsies of peripheral nerve obtained at above-knee or below-knee amputation. In diabetic patients nerve glucose (median [range]) (5.09 [1.62–12.82] vs 3.12 [1.81–4.01]) p<0.001, fructose (0.245 [0.060–1.280] vs 0.150 [0.053–0.385]) p<0.05, and sorbitol (0.028 [0.012–0.496] vs 0.016 [0.007–0.059] p<0.02, μmol/g wet weight) were significantly higher than in non-diabetic patients. No significant difference was found in myoinositol concentration (1.95 [1.00–3.55] vs 2.09 [1.27–5.40] μmol/g wet weight). Concentrations differed markedly from previously reported values in human nerve obtained at post-mortem.

Key words

Nerve glucose fructose sorbitol myoinositol 

References

  1. 1.
    Ward JD, Baker RWP, Davis BH (1972) Effect of blood sugar control on the accumulation of sorbitol and fructose in nervous tissue. Diabetes 21: 1173–1178Google Scholar
  2. 2.
    Gabbay KH (1975) Hyperglycaemia, polyol metabolism, and complications of diabetes mellitus. Ann Rev Med 26: 521–536Google Scholar
  3. 3.
    Palmano KP, Whiting PH, Hawthorne JN (1977) Free and lipid myo-inositol in tissues from rats with acute and less severe streptozotocin-induced diabetes. Biochem J 167: 229–235Google Scholar
  4. 4.
    Clements RS Jr (1979) Diabetic neuropathy — New concepts of its etiology. Diabetes 28: 604–611Google Scholar
  5. 5.
    Brownlee M, Cerami A (1981) The biochemistry of the complications of diabetes mellitus. Ann Rev Biochem 50: 385–432Google Scholar
  6. 6.
    Gillon KRW, Hawthorne JN, Tomlinson DR (1983) Myo-inositol and sorbitol metabolism in relation to peripheral nerve function in experimental diabetes in the rat: the effect of aldose reductase inhibition. Diabetologia 25: 365–371Google Scholar
  7. 7.
    Gillon KRW, Hawthorne JN (1983) Sorbitol, inositol and nerve conduction in diabetes. Life Sci 32: 1943–1947Google Scholar
  8. 8.
    Mayhew JA, Gillon KRW, Hawthorne JN (1983) Free and lipid inositol, sorbitol and sugars in sciatic nerve obtained post-mortem from diabetic patients and control subjects. Diabetologia 24: 13–15Google Scholar
  9. 9.
    Dyck PJ, Sherman WR, Hallcher LM, Service FJ, O'Brien PC, Grina LA, Palumbo PJ, Swanson CJ (1980) Human diabetic endoneural sorbitol, fructose and myo-inositol related to sural nerve morphometry. Ann Neurol 8: 590–596Google Scholar
  10. 10.
    Tomlinson DR, Moriarty RJ, Mayer H (1984) Prevention and reversal of defective axonal transport and motor nerve conduction velocity in rats with experimental diabetes by treatment with the aldose reductase inhibitor Sorbinil. Diabetes 33: 470–476Google Scholar
  11. 11.
    Stribling D, Mirrlees DJ, Harrison HE, Earl DCN (1985) Properties of ICI 128436, a novel aldose reductase inhibitor, and its effects on diabetic complications in the rat. Metabolism 34: 336–344Google Scholar
  12. 12.
    McCallum KNC, Sharma AK, Blanchard DS, Stribling D, Mirrlees DJ, Doguid M, Thomas PK (1986) The effect of continuous insulin infusion therapy on morphological and biochemical abnormalities of peripheral nerves in experimental diabetes. J Neurol Sci 74: 55–67Google Scholar
  13. 13.
    Somogyi M (1945) Determination of blood sugar. J Biol Chem 160: 69–73Google Scholar
  14. 14.
    De Neef J (1969) Quantitative determination of mixtures of monosaccharides, disaccharides and alditols as their trimethylsilyl ether derivatives by gas-liquid chromatography. Clin Chim Acta 26: 485–490Google Scholar
  15. 15.
    Cohen L, Holliday M (1982) Statistics for social scientists. Harper and Row, London, pp 239–241Google Scholar
  16. 16.
    Greene DA, De Jesus PV, Winegrad AI (1975) Effects of insulin and dietary myoinositol on impaired peripheral motor nerve conduction velocity in acute streptozotocin diabetes. J Clin Invest 55: 1326–1336Google Scholar
  17. 17.
    Clements RS Jr, Stockard CR (1980) Abnormal sciatic nerve myo-inositol metabolism in the streptozotocin-diabetic rat. Diabetes 29: 227–235Google Scholar
  18. 18.
    Brown MJ, Iwamori M, Kishimoto Y, Rapoport B, Moser HW, Asbury AK (1979) Nerve lipid abnormalities in human diabetic neuropathy: A correlative study. Ann Neurol 5: 245–252Google Scholar
  19. 19.
    Stribling D, Perkins CM (1986) Aldose reductase inhibitors. In: Nattrass M (ed) Recent advances in diabetes 2. Churchill Livingstone, Edinburgh, pp 169–176Google Scholar

Copyright information

© Springer-Verlag 1987

Authors and Affiliations

  • P. J. Hale
    • 1
  • M. Nattrass
    • 1
  • S. H. Silverman
    • 1
  • C. Sennit
    • 2
  • C. M. Perkins
    • 2
  • A. Uden
    • 3
  • G. Sundkvist
    • 4
  1. 1.Diabetic ClinicGeneral HospitalBirmingham
  2. 2.ICI PharmaceuticalsMacclesfieldUK
  3. 3.Department of OrthopaedicsUniversity of Lund, Malmo General HospitalMalmoSweden
  4. 4.Department of MedicineUniversity of Lund, Malmo General HospitalMalmoSweden

Personalised recommendations